This page is general information, not medical advice. Your own doctor or care team is the right source for questions about your skin, diagnosis or treatment.
Metastatic is a medical description of spread. It can be a difficult word to encounter, and it does not by itself explain the location of the melanoma, the information from tissue tests or the purpose of a care plan. Those details are discussed together by the care team.
This page explains the categories of treatment described by national agencies and the biological questions behind them. It does not rank those categories, suggest a sequence or estimate a person's outlook. Your care team can explain which, if any, apply to you.
What metastatic means
The National Cancer Institute's melanoma patient summary describes stage IV as spread to distant parts of the body. This may include distant lymph nodes, skin areas far from the original melanoma, or organs such as the lungs, liver or brain. The pattern differs between people.
Metastasis occurs when cells from the original cancer travel through blood or lymphatic pathways and form tumors elsewhere. A distant melanoma deposit remains melanoma. For example, melanoma in the lung is not the same diagnosis as a cancer that began in lung tissue. That distinction matters when clinicians describe the disease and its treatment categories.
The original melanoma is the primary tumor. Tissue findings, examinations and imaging contribute information about its spread. The visible size of the original skin spot does not describe every site assessed by the team. A stage term is therefore read with the clinical records, rather than as a substitute for them.
The guide to pathology reports explains tissue terminology. Reports from different samples may answer different questions, including identifying the cancer type and examining particular cell features. Your care team can explain the relationship between those findings and the imaging information.
The immune system and checkpoint inhibitors
Immunotherapy is a treatment category that works through the immune system. The NCI melanoma summary includes it among the categories used for metastatic melanoma. Your care team can explain which, if any, apply to you.
The NCI's explanation of immune checkpoint inhibitors describes checkpoints as normal controls on immune activity. They help prevent an immune response from damaging healthy cells. Proteins on immune cells can bind to partner proteins on other cells, including some cancer cells, and limit the immune response.
A checkpoint inhibitor blocks particular interactions between those proteins. The NCI describes this as allowing immune cells to act against cancer cells. That is an explanation of a treatment mechanism, rather than an assurance that a tumor will respond. The category contains different treatments, and the clinical discussion concerns the actual situation.
Understanding the mechanism also helps explain why side effects are a separate question from the intended cancer effect. Changing an immune response can affect healthy tissues as well. The care team assesses the intended purpose and the possible harms together.
Targeted therapy and gene findings
The NCI's targeted-therapy explanation describes treatment directed at proteins involved in how cancer cells grow, divide and spread. Testing looks for relevant features in a tumor. This is often called biomarker testing: laboratory assessment of characteristics that may matter to treatment selection.
Targeted therapy therefore depends on the biological target as well as the cancer diagnosis. The NCI melanoma summary identifies changes in the BRAF gene as relevant to treatment discussions. Gene changes in the cancer cells are assessed through laboratory findings; the stage label alone does not establish them.
The American Cancer Society describes BRAF inhibitors as targeting the BRAF protein and MEK inhibitors as targeting related MEK proteins. These categories concern signals involved in cancer-cell growth. These names describe what is targeted, rather than a particular medicine. Your care team can explain which, if any, of these categories apply to you and which test findings are relevant.
The NCI also explains that cancer cells can become resistant to targeted therapy. A target may change, or cells may use another route to grow. The word targeted does not mean a treatment has no risks or that its effect is certain. It describes the biological focus of the treatment.
Surgery, radiation and other categories
The NCI melanoma summary describes surgery or radiation therapy in some metastatic settings. These approaches can be directed at particular areas of disease and may be considered in relation to symptoms and quality of life. Your care team can explain which, if any, apply to you.
Surgery removes tissue. Radiation therapy uses high-energy radiation directed toward an area of cancer. Their role depends on where disease is found and the clinical aim. A local approach to a particular deposit and a treatment acting more widely in the body answer different parts of the care question.
The NCI summary also includes chemotherapy among categories discussed in some circumstances. This is a category affecting cancer-cell growth and division. Agency lists are descriptions of available approaches; they do not mean that every person receives every category. The clinical team explains the purpose and possible harms of the specific plan under discussion.
Monitoring and side effects
The NCI checkpoint-inhibitor page describes possible side effects, including fatigue, skin changes and diarrhea. It also describes inflammation that can affect different organs. It makes clear that clinicians cannot know with certainty whether a particular person will develop side effects or how severe they may be.
The targeted-therapy page similarly describes possible serious side effects and differences in how people respond. Treatment assessment therefore concerns more than whether an imaging finding changes. It also includes how the person feels, examination findings and laboratory or imaging assessments as appropriate to the treatment.
The NCI explains that tests used during treatment can help assess its effects. Your clinical team supplies the actual monitoring plan and instructions about changes they need to hear about. This reference gives no symptom-management directions, treatment schedule or dose.
How research informs the categories
A review of cutaneous melanoma published in JAMA brings together evidence on surgery, treatment through immune pathways and treatment directed at gene-related pathways. It describes checkpoint blockade in metastatic melanoma and gene-directed categories in stage-based care. This reflects a field in which treatment research examines the biology of melanoma as well as where it has spread.
The NCI targeted-therapy explanation describes research connecting DNA changes and proteins with the design of treatment approaches. It also identifies resistance as a difficulty. A mechanism and a study result supply useful context, while neither establishes that a category is suitable or effective for an individual person.
The page on clinical trials explains how research questions, eligibility, consent and costs are described. Trials may examine treatment categories or combinations, but a research study is not a guarantee of benefit. The guide to follow-up care explains the general purpose of ongoing assessments and records.
The National Cancer Institute's SEER melanoma statistics page presents group information and explains that it cannot predict an individual's outcome. This page gives no survival figures. Questions about the meaning of findings or the goals of a plan belong with your own care team.